TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03449563

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided TPVB
Description: In Group U, thoracic paravertebral block was performed on the operated side under ultrasound guidance with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: In Group G,patients were just received Patient-controlled intravenous analgesia after the surgery.
Study: NCT00442494

Intervention type: DRUG
Group type: OTHER
Intervention: intravenous hydrocortisone
Study: NCT01732029

Intervention type: OTHER
Group type: OTHER
Intervention: Normobaric hypoxia chamber
Study: NCT02889497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the first batch vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the second batch vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the third batch vaccine
Study: NCT05431231

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical decision-making style
Description: a questionnaire with two - patient and therapist - versions, meant to evaluate decision making style. It was developed by Puschner, Neumann, Jordan, et al. in 2013. The questionnaire constitutes a modified version of the Autonomy Preference Index (API), which was developed by Ende, Kazis, Ash, \& Moskowitz in 1989 for mental health patients. In the current study, only the therapist/psychiatrist version would be administered. The questionnaire is composed of 21 items and yields two components related to clinical decision making: preferences in decision making style and information seeking during decision making. Puschner et al (2013) reported that Kronbach's α coefficient ranged from 0.87 to 0.89.

Intervention type: DIAGNOSTIC_TEST
Intervention: Global Assessment of Functioning Scale
Description: a questionnaire meant to assess the patient's global functioning. It was developed by Jones, Thornicroft, Coffey, \& Dunn in 1996. The GAF was used in DSM-IV as the fifth axis of psychiatric evaluation. The therapist is asked to determine for each patient a general score ranging from 10 to 100 to describe his everyday functioning in psychological, social and occupational fields. A score of 10 refers to a state of persistent danger of severely hurting the self or others, and a score of 100 refers to superior functioning in all areas of life. Jones et al. reported that Kronbach's α ranged from 0.74 to 0.76.
Study: NCT06532929

Intervention type: DEVICE
Intervention: Orthopaedic surgeries (ankle)
Description: ankle lateral ligament reconstruction in ligamentoplasty procedures
Study: NCT02196090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention
Description: A procedure where patients with OCD test out their fears without responding by compulsive act.
Study: NCT04257487

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic sulodexide 250 LSU
Study: NCT02691169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: 18F-DCFPyL is a sterile diagnostic radiopharmaceutical used for PET imaging.
Study: NCT02196090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold face gel mask
Description: Temporary application of cold eye mask on the face is commonly used for relaxation purpose.
Study: NCT03012360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Description: 2 g iv every 24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: 400 mg iv every 8h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imipenem
Description: 1 g iv every 8h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linezolid
Description: 600 mg iv every 12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
Study: NCT04069624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOUD Pre-Treatment Telehealth
Description: Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOUD Pre-Treatment Telehealth and Peer Navigator
Description: Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth. Additionally, participants will be connected with a Peer Navigator who will meet with them via telehealth prior to release and provide ongoing support by telephone post-release.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Medications to treat opioid use disorder (MOUD) pre-treatment.
Study: NCT04816370

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FSFI
Description: 2 group and 2 subgroup

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FSFI
Description: 2 group and 2 subgroup

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FSFI
Description: 2 group and 2 subgroup

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FSFI
Description: 2 group and 2 subgroup
Study: NCT04655690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0471-0119
Description: Participants will be randomised to either of five dose levels 0.3, 0.6, 1.2, 2.4 or 3.6 of NNC0471-0119 nanomol per kilogram body weight, which will be administered as a single dose. NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fast-acting insulin aspart
Description: Participants will get a fixed dose of 0.2 units of fast-acting insulin aspart (Fiasp®) per kilogram body weight, administered subcutaneously (s.c., under the skin) in fasting state.
Study: NCT02182999

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wound infiltration catheter
Description: Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration catheter
Description: Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%
Description: The catheter is connected to the perfusor line filled with Ropivacaine 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
Study: NCT03598660

Intervention type: GENETIC
Intervention: Sorcin gene expression
Description: Sorcin gene expression Will be measured by real time PCR

Intervention type: GENETIC
Intervention: Sorcin gene expression
Description: Sorcin gene expression Will be measured by real time PCR

Intervention type: GENETIC
Intervention: Sorcin gene expression
Description: Sorcin gene expression Will be measured by real time PCR

Intervention type: OTHER
Intervention: Annexin A3 serum mesurement
Description: serum mesurement of Annexin A3 by enzyme linked immuno sorbent assay (ELISA)

Intervention type: OTHER
Intervention: Annexin A3 serum mesurement
Description: serum mesurement of Annexin A3 by enzyme linked immuno sorbent assay (ELISA)

Intervention type: OTHER
Intervention: Annexin A3 serum mesurement
Description: serum mesurement of Annexin A3 by enzyme linked immuno sorbent assay (ELISA)
Study: NCT01666990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TwHF
Description: Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
Study: NCT06532929

Intervention type: DEVICE
Intervention: Orthopaedic surgeries (ankle)
Description: ankle lateral ligament reconstruction in ligamentoplasty procedures

Intervention type: DEVICE
Intervention: Orthopaedic surgeries (shoulder)
Description: rotator cuff repair

Intervention type: DEVICE
Intervention: Orthopaedic surgeries (knee)
Description: knee cruciate ligaments reconstruction in ligamentoplasty procedures
Study: NCT01666990

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
Study: NCT00500669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betadine
Description: Topically

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betadine
Description: Topically
Study: NCT03352869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Use Exenatide for 3 months to treat PCOS
Study: NCT02671552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Protein-Type A Microspheres
Description: Given IV
Study: NCT03352869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Use Exenatide for 3 months to treat PCOS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Use Metformin for 3 months to treat PCOS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Use Metformin for 3 months to treat PCOS
Study: NCT03034109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: TDCS involves sending a weak electrical current to the brain to modulate brain functions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: TDCS involves sending a weak electrical current to the brain to modulate brain functions.
Study: NCT02671552

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Ultrasound Imaging
Description: Undergo contrast-enhanced ultrasound imaging
Study: NCT03034109

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: TDCS involves sending a weak electrical current to the brain to modulate brain functions.
Study: NCT02785432

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham low level laser
Description: Sham laser will be administered using the same time and contact exposure as delivered for the active group, but without any energy delivered.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active low level laser
Description: Active treatment will be delivered using the time, contact, and energy exposures described in the arm description.
Study: NCT01182987

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dementia Care Management
Description: The SCAN Memory Program is a care management program for cognitively-impaired SCAN members and for their informal/family caregivers. The program includes collaboration between SCAN Health Plan, partnering medical groups, and community organizations.~Program activities include: 1) telephonic-structured assessments with informal caregivers conducted by SCAN Memory Program care managers; 2) problem identification as a result of these assessments; and 3) pre-established protocols and procedures for problem resolution.
Study: NCT00897260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
Description: To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.~DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x~* Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x~* Fludarabine dose adjustment:~  70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.~UCB Infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
Description: DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
Study: NCT01101087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taurolock

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injectable sodium chloride conditioned in exactly the same manner as the experimental product.
Study: NCT04084665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab
Study: NCT03068052

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No incentive
Description: Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment.
Study: NCT06532929

Intervention type: DEVICE
Intervention: Orthopaedic surgeries (knee)
Description: knee cruciate ligaments reconstruction in ligamentoplasty procedures

Intervention type: DEVICE
Intervention: Orthopaedic surgeries (knee)
Description: knee cruciate ligaments reconstruction in ligamentoplasty procedures
Study: NCT03068052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive
Description: Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment, for which they will received a loss-framed incentive. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment and will receive an additional unconditional pro-social incentive.
Study: NCT02114398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual treatment
Description: usual treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual treatment + sophrology
Description: usual treatment + sophrology
Study: NCT03521401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants assigned to the exercise group will undergo structured, progressive resistance and aerobic exercise for 8 weeks. Resistance training and aerobic training will each be completed twice weekly for a total of 16 resistance and 16 aerobic exercise training sessions.
Study: NCT06532929

Intervention type: DEVICE
Intervention: Orthopaedic surgeries (knee)
Description: knee cruciate ligaments reconstruction in ligamentoplasty procedures

Intervention type: DEVICE
Intervention: Orthopaedic surgeries (knee)
Description: knee cruciate ligaments reconstruction in ligamentoplasty procedures

Intervention type: DEVICE
Intervention: Orthopaedic surgeries (knee)
Description: knee cruciate ligaments reconstruction in ligamentoplasty procedures

Intervention type: DEVICE
Intervention: Orthopaedic surgeries (knee)
Description: knee cruciate ligaments reconstruction in ligamentoplasty procedures

Intervention type: DEVICE
Intervention: Orthopaedic surgeries
Description: rotator cuff repair or closure of capsule after arthroplasty surgery

Intervention type: DEVICE
Intervention: Orthopaedic surgeries (foot)
Description: stabilization of metatarsal and phalangeal osteotomies during treatment of hallux
Study: NCT02447068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luma Light System
Description: The Luma Light System combines a NBUVB light with an occlusive dressing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Luma Light
Description: NBUVB light
Study: NCT01661621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detrusitol 4 mg QD
Description: Group 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg QD
Description: Group 2
Study: NCT01455259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCD40L
Description: Adenoviral serotype 5 vector, E1/E3 deleted. Human CD40L gene insert driven by RSV promoter. Vector diluted in infusion solution, 500uL solution containing 2.5x10e11 VP is intratumorally injected/treatment.
Study: NCT00763568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
Study: NCT01433991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golvatinib
Description: Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golvatinib
Description: Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golvatinib
Description: Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golvatinib
Description: Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golvatinib
Description: Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants will receive lenvatinib 1 mg and/or 4 mg and/or 10 mg capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants will receive lenvatinib 1 mg and/or 4 mg and/or 10 mg capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants will receive lenvatinib 1 mg and/or 4 mg and/or 10 mg capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants will receive lenvatinib 24 mg (1\*4 mg capsule + 2\*10 mg capsule) capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
Study: NCT02447068

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusive Dressing
Description: Off-the-shelf occlusive dressing
Study: NCT02171039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Study: NCT01293357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90105
Description: Ointment
Study: NCT02171039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study: NCT00727909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid Treatments
Description: Hearing aid treatments:~Traditional Custom (TC), Receiver-in-the Aid (RITA) and Receiver-in-the-Ear (RITE)
Study: NCT02171039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study: NCT04386473

Intervention type: DEVICE
Intervention: pacemaker
Description: electrode is implanted in left bundle branch in LBBP; electrode is implanted in right ventricular outflow tract septal in RVOP

Intervention type: DEVICE
Intervention: pacemaker
Description: electrode is implanted in left bundle branch in LBBP; electrode is implanted in right ventricular outflow tract septal in RVOP
Study: NCT04432181

Intervention type: OTHER
Intervention: ophthalmic examination
Description: ophthalmic examination including; best corrected visual acuity, alternating prism cover test, retinoscopy, fundus examination, ocular vergence evaluation

Intervention type: OTHER
Intervention: ophthalmic examination
Description: ophthalmic examination including; best corrected visual acuity, alternating prism cover test, retinoscopy, fundus examination, ocular vergence evaluation
Study: NCT00592072

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medium chain fatty acid (Octanoic and Decanoic acid)
Description: Octanoic acid(67%) and Decanoic acid (27%); MCFA 50g total at 25 minute intervals with front loading of 20g then 10g for three administrations.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Splenda (Placebo Control)
Description: Placebo drink will consist of dietary sweetener Splenda mixed in water at a concentration of 1g/100mL. An unsweetened cherry flavor Koolaid mix will be added at a concentration of 0.3g/100mL of the Splenda drink to enhance flavor.
Study: NCT03588104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POWER2DM system
Description: This system consists of two components: 1) the web-based Shared Decision Making Dashboard, used to set self-management goals together with a health care professional with the use of both short- and long-term predictive computer simulation models, and 2) the POWER2DM Self-Management Support System as a mobile application and webpage, used to support behavioural change in DM self-management. The system is fed with data from an activity tracker, a glucose monitor and manual data entry. Power2DM support will be provided as an adjunct to usual care